간암 진단 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Liver Cancer Diagnostics Market Summary

The global liver cancer diagnostics market size was estimated at USD 9.99 billion in 2024 and is projected to reach USD 17.57 billion by 2033, growing at a CAGR of 6.42% from 2025 to 2033. Liver cancer is the leading cause of death amongst all deadly diseases in the globe.

Since 1980, the rate of incidence of liver cancer has tripled and death rates have doubled during this period. The American Cancer Society estimated that in 2025, about 42,240 new cases are expected, and about 30,090 people will succumb to death. Thus, the global rise in liver cancer prevalence, combined with ongoing exposure to risk factors, will significantly accelerate the growth of the screening and diagnosis market. The rising incidence of liver cancer is increasing the demand for early-stage cancer diagnosis and efforts to reduce associated risk factors. Early detection is crucial in lowering cancer-related deaths, especially through effective screening programs. Overall, diagnosing cancer early can boost patient survival rates by 5 to 10 times compared to later detection.

As the global cases of liver cancer grow, the need for early detection tools and screening methods has intensified. For instance, the National Cancer Institute established the Liver (Hepatocellular) Cancer Screening (PDQ)-health professional version program in April 2025, utilizing techniques like needle aspiration cytology and trans jugular liver biopsy. Programs focused on high-risk groups, such as those with chronic liver conditions, are promoting greater awareness and use of diagnostic tools like ultrasound, CT scans, and blood tests. Early and regular screenings improve detection rates and patient outcomes. This increased emphasis on prevention and early diagnosis is driving innovations in liver cancer diagnostics and accelerating market growth.

Liver cancer screening and treatment are poised for a major shift thanks to cutting-edge early screening technologies currently in advanced development stages. These new innovations are paving the way for growth in the liver diagnostics market. For instance, in April 2025, the FDA granted breakthrough device designation to the EvoLiver biopsy test for monitoring hepatocellular carcinoma (HCC) in patients with high-risk cirrhosis. The test uses a multiomics biomarker signature based on extracellular vesicles (EV) and has shown promising results in detecting early-stage HCC. Data from the MEV01 trial, which involved 464 patient samples, indicated that the EvoLiver test achieved an impressive 86% sensitivity and 88% specificity for early-stage HCC detection. These results significantly surpass current surveillance methods like ultrasound and alpha-fetoprotein testing. This innovative approach has the potential to improve the management of hepatocellular carcinoma in cirrhotic patients greatly.

Global Liver Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global liver cancer diagnostics market report on the basis of test type, end-use, and region:

• Test type Outlook (Revenue, USD Million, 2021 - 2033)
• Laboratory Tests
  • Biomarkers
  • Oncofetal and Glycoprotein Antigens
  • Enzymes and Isoenzymes
  • Growth Factors and Receptors
  • Molecular Markers
  • Pathological Biomarkers
  • Blood Tests
• Imaging
• Endoscopy
• Biopsy
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & CRO Laboratories
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test type
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test type outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Incidence of Liver Cancer
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Extensive R&D For Developing Novel Testing Solutions
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Diagnostic imaging
• 3.3. Liver Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Liver Cancer Diagnostics Market: Product Movement Analysis
• 4.3. Liver Cancer Diagnostics Market Size & Trend Analysis, by test type, 2021 to 2033 (USD Million)
  • 4.3.1. Global Laboratory Tests Market, 2021 - 2033 (USD MILLION)
    • 4.3.1.1. Biomarkers
      • 4.3.1.1.1. Global biomarkers market, 2021 - 2033 (USD million)
        • 4.3.1.1.1.1. Oncofetal and Glycoprotein Antigens
          • 4.3.1.1.1.1.1. Global oncofetal and glycoprotein antigens market, 2021 - 2033 (USD million)
        • 4.3.1.1.1.2. Enzymes and Isoenzymes
          • 4.3.1.1.1.2.1. Global enzymes and isoenzymes market, 2021 - 2033 (USD million)
        • 4.3.1.1.1.3. Growth Factors and Receptors
          • 4.3.1.1.1.3.1. Global growth factors and receptors market, 2021 - 2033 (USD million)
        • 4.3.1.1.1.4. Molecular Markers
          • 4.3.1.1.1.4.1. Global molecular markers market, 2021 - 2033 (USD million)
        • 4.3.1.1.1.5. Pathological Biomarkers
          • 4.3.1.1.1.5.1. Global pathological biomarkers market, 2021 - 2033 (USD million)
    • 4.3.1.2. Blood Tests
      • 4.3.1.2.1. Global blood tests market, 2021 - 2033 (USD million)
  • 4.3.2. Imaging
    • 4.3.2.1. Global Imaging Market, 2021 - 2033 (USD MILLION)
  • 4.3.3. Endoscopy
    • 4.3.3.1. Global Endoscopy Market, 2021 - 2033 (USD MILLION)
  • 4.3.4. Biopsy
    • 4.3.4.1. Global Biopsy Market, 2021 - 2033 (USD MILLION)

Chapter 5. Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Liver Cancer Diagnostics Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Hospitals & Diagnostic Laboratories
  • 5.5.1. Global Hospitals & Diagnostic Laboratories market, 2021 - 2033 (USD Million)
• 5.6. Academic & Research Institutes
  • 5.6.1. Global Academic & Research Institutes Market, 2021 - 2033 (USD million)
• 5.7. Pharmaceutical & CRO Laboratories
  • 5.7.1. Global Pharmaceutical & CRO Laboratories market, 2021 - 2033 (USD million)

Chapter 6. Liver Cancer Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 6.5. North America
  • 6.5.1. North America: SWOT Analysis
  • 6.5.2. U.S.
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/Reimbursement
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/Reimbursement
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/Reimbursement
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe: SWOT Analysis
  • 6.6.2. UK
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/Reimbursement
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/Reimbursement
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/Reimbursement
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/Reimbursement
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/Reimbursement
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.7. Norway
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/Reimbursement
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/Reimbursement
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.9. Denmark
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory framework/Reimbursement
    • 6.6.9.3. Competitive scenario
    • 6.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Asia Pacific: SWOT Analysis
  • 6.7.2. Japan
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/Reimbursement
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.3. China
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/Reimbursement
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.4. India
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/Reimbursement
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.5. Australia
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/Reimbursement
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.6. South Korea
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/Reimbursement
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.7. Thailand
    • 6.7.7.1. Key country dynamics
    • 6.7.7.2. Regulatory framework/Reimbursement
    • 6.7.7.3. Competitive scenario
    • 6.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. Latin America
  • 6.8.1. Latin America: SWOT Analysis
  • 6.8.2. Brazil
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/Reimbursement
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/Reimbursement
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 6.9. MEA
  • 6.9.1. MEA: SWOT Analysis
  • 6.9.2. South Africa
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/Reimbursement
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/Reimbursement
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.9.4. UAE
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/Reimbursement
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key country dynamics
    • 6.9.5.2. Regulatory framework
    • 6.9.5.3. Competitive scenario
    • 6.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. Abbott Laboratories
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Services benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Thermo Fisher Scientific, Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Services benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. F. Hoffmann-La Roche Ltd.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Services benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Qiagen N.V.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Services benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Siemens Healthineers
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Services benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Becton, Dickinson & Company
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Services benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Illumina, Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Services benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Epigenomics AG
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Services benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Koninklijke Philips N.V.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Services benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Fujifilm Medical Systems U.S.A., Inc.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Services benchmarking
    • 7.3.13.4. Strategic initiatives